S&P 500 · SPY
772.31
▲ +2.65 (+0.34%)
DOW JONES · DIA
524.68
▲ +1.40 (+0.27%)
NASDAQ · QQQ
725.61
▲ +4.36 (+0.60%)
GOLD · GLD
$373.51
▲ +1.23 (+0.33%)
OIL (WTI) · USO
$166.57
▲ +2.69 (+1.64%)
BITCOIN
$80,123.76
▼ -1,091.54 (-1.34%)
--:--:--
NYSE · Live ET

Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Summary from the CNBC news feed. Copyright belongs to CNBC.

Read full story at CNBC ↗

Opens in a new tab, so Investz stays open.

ShareEmailXLinkedInFacebookRedditWhatsApp

More headlines

All news
CNBCMerck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strengthMarketWatchLilly raises outlook for third time this year as Zepbound sales soarCNBCU.S. worker job engagement hits lowest level since 2011, new Gallup poll findsCNBCPresident of the European Central Bank Christine Lagarde to step down in FebruaryMarketWatchWe’re in our 70s. Should we pay off our 2.5% mortgage — or put the money in a high-yield savings account?MarketWatchThe Fed held off on a rate hike. Today’s GDP and inflation reports could make waiting harder.

Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.